Shilpa Medicare Ltd
Shilpa Medicare is engaged in the business of manufacturing of API, Formulation and Development service.
- Market Cap ₹ 3,133 Cr.
- Current Price ₹ 384
- High / Low ₹ 695 / 233
- Stock P/E 24.4
- Book Value ₹ 179
- Dividend Yield 0.29 %
- ROCE 12.4 %
- ROE 12.4 %
- Face Value ₹ 1.00
Pros
- No pros found. Suggest something.
Cons
- The company has delivered a poor sales growth of 8.14% over past five years.
- Company has a low return on equity of 10.11% for last 3 years.
- Company might be capitalizing the interest cost
- Earnings include an other income of Rs.93.04 Cr.
- Dividend payout has been low at 6.14% of profits over last 3 years
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
234.46 | 198.17 | 162.28 | 173.43 | 199.52 | 160.99 | 289.92 | 236.85 | 219.99 | 222.86 | 278.94 | 191.25 | |
188.55 | 148.90 | 127.82 | 147.25 | 162.11 | 132.20 | 222.59 | 163.11 | 174.77 | 157.74 | 210.54 | 170.75 | |
Operating Profit | 45.91 | 49.27 | 34.46 | 26.18 | 37.41 | 28.79 | 67.33 | 73.74 | 45.22 | 65.12 | 68.40 | 20.50 |
OPM % | 19.58% | 24.86% | 21.23% | 15.10% | 18.75% | 17.88% | 23.22% | 31.13% | 20.56% | 29.22% | 24.52% | 10.72% |
Other Income | 6.78 | 4.36 | 29.22 | -2.60 | 3.13 | 2.34 | 5.82 | 3.94 | 8.91 | 66.32 | 9.20 | 8.61 |
Interest | 1.05 | 0.58 | 0.63 | 1.07 | 1.41 | 1.46 | 0.82 | 1.27 | 1.01 | 4.00 | 3.95 | 4.80 |
Depreciation | 10.77 | 10.26 | 10.00 | 11.25 | 10.54 | 10.66 | 10.66 | 10.97 | 11.55 | 12.33 | 12.70 | 13.72 |
Profit before tax | 40.87 | 42.79 | 53.05 | 11.26 | 28.59 | 19.01 | 61.67 | 65.44 | 41.57 | 115.11 | 60.95 | 10.59 |
Tax % | 25.03% | 22.53% | 21.49% | -4.09% | 19.62% | 21.30% | 18.14% | 16.08% | 18.16% | 25.31% | 26.25% | 27.48% |
Net Profit | 30.90 | 33.64 | 42.27 | 12.47 | 23.88 | 15.74 | 50.78 | 55.06 | 34.57 | 86.31 | 45.38 | 7.67 |
EPS in Rs | 3.79 | 4.13 | 5.18 | 1.53 | 2.93 | 1.93 | 6.23 | 6.75 | 4.24 | 10.59 | 5.57 | 0.94 |
Notes | Notes | Notes | Notes | Notes | Notes | Notes | Notes | Notes | Notes | Notes | Notes |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
166 | 265 | 290 | 318 | 371 | 571 | 614 | 719 | 779 | 789 | 733 | 908 | 913 | |
144 | 184 | 216 | 257 | 301 | 458 | 485 | 566 | 619 | 634 | 606 | 688 | 714 | |
Operating Profit | 22 | 81 | 74 | 61 | 70 | 113 | 128 | 153 | 161 | 155 | 128 | 219 | 199 |
OPM % | 13% | 30% | 26% | 19% | 19% | 20% | 21% | 21% | 21% | 20% | 17% | 24% | 22% |
Other Income | 1 | 2 | 5 | 9 | 5 | 9 | 5 | 5 | 20 | 22 | 54 | 17 | 93 |
Interest | 6 | 6 | 3 | 2 | 2 | 4 | 4 | 7 | 3 | 3 | 4 | 5 | 14 |
Depreciation | 9 | 13 | 13 | 14 | 15 | 23 | 21 | 29 | 31 | 37 | 42 | 44 | 50 |
Profit before tax | 8 | 64 | 64 | 53 | 57 | 95 | 108 | 122 | 146 | 137 | 136 | 188 | 228 |
Tax % | 112% | 33% | 23% | 23% | 17% | 21% | 33% | 19% | 29% | 25% | 19% | 18% | |
Net Profit | -1 | 43 | 49 | 41 | 47 | 76 | 74 | 104 | 108 | 105 | 112 | 156 | 174 |
EPS in Rs | -0.13 | 6.46 | 6.84 | 5.61 | 6.44 | 10.28 | 9.56 | 13.46 | 13.43 | 12.91 | 13.77 | 19.15 | 21.34 |
Dividend Payout % | -124% | 4% | 4% | 5% | 7% | 5% | 6% | 4% | 4% | 5% | 7% | 6% |
Compounded Sales Growth | |
---|---|
10 Years: | 13% |
5 Years: | 8% |
3 Years: | 5% |
TTM: | 3% |
Compounded Profit Growth | |
---|---|
10 Years: | 14% |
5 Years: | 16% |
3 Years: | 15% |
TTM: | -12% |
Stock Price CAGR | |
---|---|
10 Years: | 18% |
5 Years: | -3% |
3 Years: | -3% |
1 Year: | -18% |
Return on Equity | |
---|---|
10 Years: | 13% |
5 Years: | 11% |
3 Years: | 10% |
Last Year: | 12% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Sep 2020 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4 | 4 | 5 | 5 | 5 | 7 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | |
Reserves | 54 | 97 | 214 | 271 | 316 | 389 | 539 | 639 | 979 | 1,077 | 1,189 | 1,321 | 1,453 |
Borrowings | 113 | 77 | 57 | 61 | 132 | 118 | 189 | 221 | 241 | 191 | 194 | 390 | 613 |
49 | 82 | 63 | 96 | 99 | 163 | 169 | 194 | 244 | 223 | 218 | 267 | 413 | |
Total Liabilities | 221 | 260 | 338 | 433 | 551 | 678 | 905 | 1,062 | 1,472 | 1,499 | 1,610 | 1,986 | 2,486 |
145 | 148 | 146 | 167 | 181 | 294 | 316 | 580 | 492 | 534 | 558 | 650 | 878 | |
CWIP | 4 | 3 | 3 | 58 | 129 | 111 | 222 | 95 | 141 | 210 | 429 | 666 | 591 |
Investments | 2 | 3 | 4 | 68 | 50 | 10 | 66 | 53 | 253 | 140 | 2 | 10 | 45 |
71 | 107 | 185 | 141 | 191 | 262 | 301 | 334 | 587 | 615 | 621 | 659 | 972 | |
Total Assets | 221 | 260 | 338 | 433 | 551 | 678 | 905 | 1,062 | 1,472 | 1,499 | 1,610 | 1,986 | 2,486 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
30 | 54 | 43 | 57 | 44 | 70 | 69 | 129 | 37 | 45 | 147 | 124 | |
-53 | -18 | -12 | -152 | -95 | -49 | -196 | -106 | -257 | -10 | -196 | -289 | |
12 | -37 | 54 | 10 | 66 | -28 | 136 | -20 | 313 | -61 | 10 | 176 | |
Net Cash Flow | -11 | -1 | 85 | -86 | 15 | -8 | 9 | 3 | 93 | -26 | -39 | 10 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
ROCE % | 9% | 40% | 29% | 18% | 15% | 20% | 18% | 16% | 14% | 10% | 9% | 12% |
Debtor Days | 52 | 48 | 50 | 47 | 41 | 43 | 48 | 43 | 80 | 102 | 101 | 98 |
Inventory Turnover | 3.05 | 3.45 | 3.64 | 3.49 | 3.18 | 3.36 | 2.71 | 2.67 | 2.26 | 2.03 | 1.54 | 1.53 |
Documents
Add documentRecent announcements
- Shilpa Medicare Limited Receives US FDA Tentative Approval For Apremilast Tablets, 10 Mg, 20 Mg, And 30 Mg 28m
- Shilpa Medicare Limited Enters Into Gynecology Segment By Launching Its First Women Intimate Cleansing Spray In India Under The Brand Name 'Swatchshil' 1d
- Announcement U/R 30 Of SEBI (LODR) Regulations 2015 18 Feb
- Announcement U/R 30 Of SEBI (LODR) Regulations 2015 18 Feb
- Intimation Under Regulation 30 Of SEBI (LODR) 2015 15 Feb
View all
Annual reports
- Financial Year 2020 from bse
- Financial Year 2019 from bse
- Financial Year 2018 from bse
- Financial Year 2017 from bse
- Financial Year 2016 from bse
- Financial Year 2015 from bse
- Financial Year 2014 from bse
- Financial Year 2013 from bse
- Financial Year 2013 from nse
- Financial Year 2012 from bse
- Financial Year 2011 from bse
- Financial Year 2010 from bse
- Financial Year 2010 from nse